Seoul plans hospital-only abortion pills by the first quarter of 2027

South Korea will try to put medical abortion pills into hospitals by the first quarter of 2027, limited to pregnancies of nine weeks or less. Prime Minister Han Seong-sook announced the plan on Wednesday, 16 September, at a government policy coordination meeting in the central government complex in Seoul. Gender Equality Minister Won Min-kyong, the health ministry and the Ministry of Food and Drug Safety presented the details.

For the first two years, both the prescription and the dispensing must happen inside a hospital or clinic. After that, if the government judges the conditions met, doctors would prescribe and pharmacies would dispense. Han said safety comes first and that women were using “dangerous methods” while the law sat unfinished.

The Constitutional Court struck down the criminal ban on abortion in 2019. The National Assembly did not pass a replacement statute. Surgical abortion has continued in a legal grey zone. Pills have not been licensed. President Lee Jae Myung told a Cabinet meeting on 14 July that leaving the gap unattended was irresponsible and asked officials to look at Mifegyne even before a new law exists.

The drug on the desk

The food and drug safety ministry has applications in hand for pills usable up to nine weeks, or 63 days after conception. One candidate is Mifegymiso, to be sold locally as Mifegyne by Hyundai Pharm. The product combines mifepristone with a prostaglandin. France approved mifepristone in 1988. About 100 countries now permit some form of the regimen.

A ministry official said the first-quarter 2027 target holds only if the safety and quality review is finished. That is an administrative clock, not a parliamentary one. The government is using existing drug-approval powers to fill a hole that legislators left open for seven years.

Doctors’ groups want tight medical control and legal cover if a complication occurs. Women’s groups want wider access and a shorter list of gatekeepers. The two-year hospital-only phase is the compromise the ministries chose. It keeps the pills inside institutions that already handle surgical cases, and it delays the pharmacy step that would make the drugs easier to obtain in towns without an obstetric ward.

What the vacuum produced

Without a statute, clinics have set their own limits. Some refuse the procedure. Others offer it quietly. Pills have arrived through unofficial channels, without verified dosing or follow-up. Han used that fact as the public reason for acting now. Won said decisions about pregnancy shape a woman’s whole life and that the institutional gap had blocked safe access to the medical system.

Han also said the government was taking “concerns regarding the value of life” seriously. That sentence is aimed at lawmakers and churches that still want a new criminal frame. The pill plan does not write that frame. It licenses a drug for a nine-week window and parks the harder argument in the Assembly, where it has sat since 2019.

If the review slips, the first-quarter date slips with it. If the Assembly finally passes a statute, the hospital rules may have to be rewritten to match it. Until one of those events happens, the operational fact is this: South Korea intends to approve a mifepristone combination for hospital use up to nine weeks, and it intends to keep pharmacies out of that trade for two years after launch.